- Home
- SPCE vs PBYI Comparison
SPCE vs PBYI Comparison
Compare SPCE & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- PBYI
- Stock Information
- Founded
- SPCE 2017
- PBYI 2010
- Country
- SPCE United States
- PBYI United States
- Employees
- SPCE N/A
- PBYI N/A
- Industry
- SPCE Transportation Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- PBYI Health Care
- Exchange
- SPCE Nasdaq
- PBYI Nasdaq
- Market Cap
- SPCE 187.2M
- PBYI 171.7M
- IPO Year
- SPCE N/A
- PBYI N/A
- Fundamental
- Price
- SPCE $3.23
- PBYI $4.66
- Analyst Decision
- SPCE Hold
- PBYI Strong Buy
- Analyst Count
- SPCE 6
- PBYI 1
- Target Price
- SPCE $9.54
- PBYI $7.00
- AVG Volume (30 Days)
- SPCE 2.2M
- PBYI 648.1K
- Earning Date
- SPCE 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- SPCE N/A
- PBYI N/A
- EPS Growth
- SPCE N/A
- PBYI 434.29
- EPS
- SPCE N/A
- PBYI 0.97
- Revenue
- SPCE $1,698,000.00
- PBYI $238,062,000.00
- Revenue This Year
- SPCE N/A
- PBYI N/A
- Revenue Next Year
- SPCE $2,869.26
- PBYI N/A
- P/E Ratio
- SPCE N/A
- PBYI $4.76
- Revenue Growth
- SPCE N/A
- PBYI 8.63
- 52 Week Low
- SPCE $2.18
- PBYI $2.32
- 52 Week High
- SPCE $8.19
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- SPCE 50.17
- PBYI 51.67
- Support Level
- SPCE $3.12
- PBYI N/A
- Resistance Level
- SPCE $3.46
- PBYI $5.22
- Average True Range (ATR)
- SPCE 0.14
- PBYI 0.23
- MACD
- SPCE 0.03
- PBYI -0.28
- Stochastic Oscillator
- SPCE 51.04
- PBYI 85.66
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.